Korean J Physiol Pharmacol.  2008 Feb;12(1):7-12. 10.4196/kjpp.2008.12.1.7.

Ameliorating Effects of Sulfonylurea Drugs on Insulin Resistance in Otsuka Long-Evans Tokushima Fatty Rats

Affiliations
  • 1Department of Physiology and Chronic Disease Research Center, Keimyung University School of Medicine, Daegu 700-712, Korea. dksong@kmu.ac.kr; dksong@dsmc.or.kr
  • 2Department of Pathology, Keimyung University School of Medicine, Daegu 700-712, Korea.

Abstract

OLETF (Otsuka Long-Evans Tokushima Fatty) rats are characterized by obesity-related insulin resistance, which is a phenotype of type 2 diabetes. Sulfonylurea drugs or benzoic acid derivatives as inhibitors of the ATP-sensitive potassium (KATP) channel are commercially available to treat diabetes. The present study compared sulfonylurea drugs (glimepiride and gliclazide) with one of benzoic acid derivatives (repaglinide) in regard to their long-term effect on ameliorating insulin sensitivity in OLETF rats. Each drug was dissolved and fed with drinking water from 29 weeks of age. On high glucose loading at 45 weeks of age, response of blood glucose recovery was the greatest in the group treated with glimepiride. On immunohistochemistry analysis for the Kir6.2 subunit of KATP channels, insulin receptor beta-subunits, and glucose transporters (GLUT) type 2 and 4 in liver, fat and skeletal muscle tissues, the sulfonylurea drugs (glimepiride and gliclazide) were more effective than repaglinide in recovery from their decreased expressions in OLETF rats. From these results, it seems to be plausible that KATP-channel inhibitors containing sulfonylurea moiety may be much more effective in reducing insulin resistance than those with benzoic acid moiety. In contrast to gliclazide, non-tissue selectivity of glimepiride on KATP channel inhibition may further strengthen an amelioration of insulin sensitivity unless considering other side effects.

Keyword

Diabetic rat; Sulfonylureas; KATP channel; Glucose transporters

MeSH Terms

Animals
Benzoic Acid
Blood Glucose
Carbamates
Drinking Water
Gliclazide
Glucose
Immunohistochemistry
Insulin
Insulin Resistance
KATP Channels
Liver
Muscle, Skeletal
Phenotype
Piperidines
Potassium
Rats
Rats, Inbred OLETF
Receptor, Insulin
Sulfonylurea Compounds
Benzoic Acid
Blood Glucose
Carbamates
Drinking Water
Gliclazide
Glucose
Insulin
KATP Channels
Piperidines
Potassium
Receptor, Insulin
Sulfonylurea Compounds

Figure

  • Fig. 1. Effect of gliclazide, glimepiride or repaglinide on changes in blood glucose level in response to high glucose loading (2 g/kg, i.p.) in LETO and OLETF rats. Each drug was dissolved in drinking water during 29 through 44 weeks of age. The experiments were done with rats aged at 45 weeks, after fasting for 12 h before the experiments. Data represent mean±S.E. # p<0.05 compared to the value of OLETF control rats at the same time period. n=7 except LETO group (n=5).

  • Fig. 2. Representative photomicrographs of Kir6.2 staining in murine fat and liver. (A) Kir6.2 is expressed in the cell membrane of adipocytes in LETO rat, whereas Kir6.2 staining is markedly reduced in OLETF rat. It is recovered by treatment with gliclazide or glimepiride. (B) Kir6.2 is expressed on the sinusoids of hepatocytes in LETO rat, but it is markedly reduced in OLETF rat. Staining is increased at the sinusoids by treatment with gliclazide, repaglinide or glimepiride.

  • Fig. 3. Representative photomicrographs of IR-β staining in murine fat and liver. (A) IR-β is expressed in the cell membrane of adipocytes of LETO rat, whereas staining is less in the cytoplasmic membrane in OLETF rat. It is recovered by treatment with gliclazide or glimepiride. (B) IR-β is strongly expressed on the sinusoids of hepatocytes in LETO rat, but it is markedly reduced in OLETF rat. Staining is increased at the sinusoids by treatment with gliclazide or glimepiride.

  • Fig. 4. Representative photomicrographs of GLUT-2 staining in murine liver. GLUT-2 is expressed in the sinusoids of hepatocytes in LETO rat, whereas GLUT-2 immunoreactivity is reduced in OLETF rat. In the groups treated with gliclazide, repaglinide, or glimepiride, GLUT-2 expression is enhanced.

  • Fig. 5. Representative photomicrographs of GLUT-4 staining in murine fat and skeletal muscles. (A) GLUT-4 is expressed in the cell membrane of adipocytes in LETO rat, whereas staining is faintly present in OLETF rat. In the groups treated with gliclazide or glimepiride, expression of GLUT-4 is markedly increased. (B) GLUT-4 is expressed in the sarcolemma of skeletal muscles of LETO rat, whereas staining is reduced in OLETF rat. In the groups treated with gliclazide or glimepiride, the expression of GLUT-4 is increased.


Cited by  1 articles

Effects of Fluvastatin on the Pharmacokinetics of Repaglinide: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Fluvastatin
Chong-Ki Lee, Jun-Shik Choi, Joon Seok Bang
Korean J Physiol Pharmacol. 2013;17(3):245-251.    doi: 10.4196/kjpp.2013.17.3.245.


Reference

Abel ED., Peroni O., Kim JK., Kim YB., Boss O., Hadro E., Minnemann T., Shulman GI., Kahn BB. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 409:729–733. 2001.
Article
Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 115:2047–2058. 2005.
Article
Bajaj M., Defronzo RA. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 10:311–323. 2003.
Article
Boyd JJ., Contreras I., Kern M., Tapscott EB., Downes DL., Frisell WR., Dohm GL. Effect of a high-fat-sucrose diet on in vivo insulin receptor kinase activation. Am J Physiol. 259:E111–116. 1990.
Eisenberg ML., Maker AV., Slezak LA., Nathan JD., Sritharan KC., Jena BP., Geibel JP., Andersen DK. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem. 15:51–58. 2005.
Article
Handberg A., Vaag A., Damsbo P., Beck-Nielsen H., Vinten J. Expression of insulin regulatable glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 33:625–627. 1990.
Article
Hughes VA., Fiatarone MA., Fielding RA., Kahn BB., Ferrara CM., Shepherd P., Fisher EC., Wolfe RR., Elahi D., Evans WJ. Exercise increases muscle GLUT-4 levels and insulin action in subjects with impaired glucose tolerance. Am J Physiol. 264:E855–862. 1993.
Article
Kahn BB. Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes. 45:1644–1654. 1996.
Article
Kawamori R., Morishima T., Kubota M., Matsuhisa M., Ikeda M., Kamada T. Influence of oral sulfonylurea agents on hepatic glucose uptake. Diabetes Res Clin Pract. 28(Suppl):S109–113. 1995.
Article
Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 41:1422–1428. 1992.
Article
Kern PA., Saghizadeh M., Ong JM., Bosch RJ., Deem R., Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 95:2111–2119. 1995.
Article
Koike T., Tomoda F., Kinuno H., Inoue H., Takata M. Abnormal renal structural alterations during the development of diabetes mellitus in Otsuka Long-Evans Tokushima Fatty rats. Acta Physiol Scand. 184:73–81. 2005.
Article
Kumar N., Dey CS. Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. J Exp Biol. 205:3739–3746. 2002.
Article
Lebovitz HE., Feinglos MN., Bucholtz HK., Lebovitz FL. Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs. J Clin Endocrinol Metab. 45:601–604. 1977.
Article
Marin P., Rebuffe-Scrive M., Smith U., Bjorntorp P. Glucose uptake in human adipose tissue. Metabolism. 36:1154–1160. 1987.
Article
Miki T., Nagashima K., Tashiro F., Kotake K., Yoshitomi H., Tamamoto A., Gonoi T., Iwanaga T., Miyazaki J., Seino S. Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. Proc Natl Acad Sci U S A. 95:10402–10406. 1998.
Minami K., Morita M., Saraya A., Yano H., Terauchi Y., Miki T., Kuriyama T., Kadowaki T., Seino S. ATP-sensitive K+ channel-mediated glucose uptake is independent of IRS-1/phosphatidylinositol 3-kinase signaling. Am J Physiol Endocrinol Metab. 285:E1289–1296. 2003.
Mori Y., Komiya H., Kurokawa N., Tajima N. Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity. Diabetes Obes Metab. 6:28–34. 2004.
Article
Muller G., Satoh Y., Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract. 28(Suppl):S115–137. 1995.
Pedersen O., Bak JF., Andersen PH., Lund S., Moller DE., Flier JS., Kahn BB. Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes. 39:865–870. 1990.
Article
Rodriguez E., Pulido N., Romero R., Arrieta F., Panadero A., Rovira A. Phosphatidylinositol 3-kinase activation is required for sulfonylurea stimulation of glucose transport in rat skeletal muscle. Endocrinology. 145:679–685. 2004.
Proks P., Reimann F., Green N., Gribble F., Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 51(Suppl 3):S368–376. 2002.
Article
Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten GE., Shaw KM. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 34:535–542. 2004.
Article
Toide K., Man ZW., Asahi Y., Sato T., Nakayama N., Noma Y., Oka Y., Shima K. Glucose transporter levels in a male spontaneous non-insulin-dependent diabetes mellitus rat of the Otsuka Long-Evans Tokushima Fatty strain. Diabetes Res Clin Pract. 38:151–160. 1997.
Article
UKPDS. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352:837–853. 1998.
Wang R., Liu X., Hentges ST., Dunn-Meynell AA., Levin BE., Wang W., Routh VH. The regulation of glucose-excited neurons in the hypothalamic arcuate nucleus by glucose and feeding-relevant peptides. Diabetes. 53:1959–1965. 2004.
Article
Wasada T., Yano T., Ohta M., Yui N., Iwamoto Y. ATP-Sensitive potassium channels modulate glucose transport in cultured human skeletal muscle cells. Endocr J. 48:369–375. 2001.
Article
Full Text Links
  • KJPP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr